The biological basis for antiangiogenic therapy.
Giavazzi
R
R
Mario Negri Institute for Pharmacological Research, Via Gavazzeni 11, Bergamo, Italy. giavazzi@cyberg.it
Albini
A
A
Bussolino
F
F
DeBraud
F
F
Presta
M
M
Ziche
M
M
Costa
A
A
D016228:Endothelial Growth Factors / Q000037:antagonists & inhibitors / Q000502:physiology; D004730:Endothelium, Vascular / Q000187:drug effects; D006801:Humans; D007558:Italy; D008222:Lymphokines / Q000037:antagonists & inhibitors / Q000502:physiology; D009369:Neoplasms / Q000098:blood supply / Q000188:drug therapy*; D009389:Neovascularization, Pathologic / Q000188:drug therapy*; D020794:Receptor Protein-Tyrosine Kinases / Q000187:drug effects; D017978:Receptors, Growth Factor / Q000187:drug effects; D040262:Receptors, Vascular Endothelial Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors
D016228:Endothelial Growth Factors; D008222:Lymphokines; D017978:Receptors, Growth Factor; D042461:Vascular Endothelial Growth Factor A; D042442:Vascular Endothelial Growth Factors; D020794:Receptor Protein-Tyrosine Kinases; D040262:Receptors, Vascular Endothelial Growth Factor